Ohtsu, Atsushi PhD
Leading researcher
with 746 publications
in the last 36 years
ORCID:
0000-0003-1329-0628
Atsushi Ohtsu, MD, PhD Director, National Cancer Center Hospital East Email: aohtsu@east.ncc.go.jp Dr Atsushi Ohtsu received his MD in 1983 and PhD in 1992 from Tohoku University in Sendai, Japan. From 1992, he has been working at Gastrointestinal Oncology department in National Cancer Center Hospital East excluding the period of his visit to MD Anderson Cancer Center, USA in 1997. In 2012, he has become the Director of Exploratory Oncology Research & Clinical Trial Center (NCC-EPOC), which involves preclinical, TR, and early/exploratory clinical research in NCC. During the period between 2015 and 2016, he had acted as a scientific board member of Japan Agency for Medical Research and Development (AMED). In 2016, he became the Director of National Cancer Center Hospital East. He has published more than 350 articles that have appeared in peer-reviewed journals such as NEJM, the Lancet, Journal of Clinical Oncology, Lancet Oncology, and the Journal of the National Cancer Institute. Dr. Ohtsu is also acting as a Director of the Japanese Society of Medical Oncology (serving as the chair of international affair committee) and Japanese Cancer Association. He is also serving as a member or advisory expert of various committees in PMDA, MHLW, and MEXT. Professional interests and specialties 1. Medical Oncology 2. Developmental Therapeutics Selected Publications 1) Izumi H, Matsumoto S, Ohtsu A, et al: The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature Dec;600(7888):319-323, 2021 2) Nakamura Y, Okamoto W, Ohtsu A, et al: Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nature Med Nov;27(11):1899-1903, 2021 3) Yamazaki K, Yamanaka T, Ohtsu A. et al: Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. Ann Oncol 32: 77-84, 2021 4) NakamuraY, Fujisawa T, Ohtsu A, et al: SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors. Cancer Sci Nov;112(11):4425-4432, 2021 5) Nakamura Y, Taniguchi H, Ohtsu A. et al: Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26: 1859-1864, 2020 6) Yoshino T, Yamanaka T, Ohtsu A. et al: Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial. JAMA Oncol 5: 1574-0581, 2019 7) Tabernero J, Hoff PM, Ohtsu A. et al: Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19: 1372-1384, 2018 8) Shitara K, Özgüroğlu M, Ohtsu A et al; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. 9) Shinozaki E, Yoshino T, Ohtsu A, et al: Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Br J Cancer. 2017 Nov 7;117(10):1450-1458 10) Kuboki Y, Nishina T, Ohtsu A, et al: TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol 18(9):1172-1181, 2017 11) Yoh K, Seto T, Ohtsu A, et al: Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): a
show More
Preview
Evolution over the last 10 years of activity
Aggregated career metrics
746
Total documents
3.54
Normalized Impact
142
Highly Cited Papers (10%)
27.61
International Collab. (%)
Most cited publications
Main coauthors
Following you can review Atsushi's accomplishments in each of the dimensions.
The perfect present for a young Researcher!
Let's do it!
Dimensions One by One
Spanning 73 diverse indicators, the dimensions considered capture a comprehensive spectrum of academic
attributes.
Each dimension includes a set of indicators and has a especific weight on the One Index.
More information here...
Activity
984
/1000
Reflects an author's research output.
Impact
886
/1000
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
Excellence
908
/1000
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
Leadership
752
/1000
Reflects an author's efforts and commitment in leading research initiatives.
Cooperation
786
/1000
Reflects a researcher's ability to navigate and thrive in varied academic and research environments, highlighting adaptability, resourcefulness, and the capacity to build and maintain collaborative relationships across the spectrum of their career.
Openness
851
/1000
Reflects an author's commitment to making their research freely accessible and open to the public.
Community Support
161
/1000
Reflects an author's contributions to the academic community beyond their own research.
Community Recognition
0
/1000
Reflects the academic community's acknowledgment and appreciation of an author's contributions.
Transference
0
/1000
Reflects an author's commitment to making their research a practical application and real-world impact of an author's research.
Fundraising
0
/1000
Reflects an author's ability in securing project funding from major global entities, showcasing your ability to drive research initiatives forward.
All indicators
Performance
Activity
Reflects an author's research output.
| Documents | 746 | Count of all document types. |
|---|---|---|
| Docs/Year | 20.72 | Average of documents published by author per year. |
| Citable docs | 741 | Count of journal articles, proceeding papers and reviews. |
| Journal Articles | 717 | Documents published as articles in scientific journals usually peer-reviewed. |
| Conferences | 1 | Original article reporting data presented at a conference or symposium. |
| Reviews | 23 | Review papers authored by the researcher. |
| Patents | 0 | Intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an enabling disclosure of the invention. |
| Theses | 0 | Document submitted in support of candidature for an academic degree or professional qualification presenting the author's research and findings |
| Books | 0 | A whole monograph or the entire book. |
| Book Chapters | 0 | Complete chapter in a book or book series volume where the item is identified as a chapter by a heading or section indicator. |
| Datasets | 11 | Number of dataset where the author have contributed to the creation. |
| Editorials | 0 | Papers where the author contributed editorial content. |
| Reports | 0 | Research reports or white papers authored. |
| Grants | 0 | Research projects funded through external grants awarded to the author. |
| Pre-Prints | 0 | Number of publications freely available in pre-print format. |
| Clinical Trials | N/A | Number of clinical trials where the author has participated. |
| Other types | 0 | Other type of documents. |
Impact
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
| Citations | 38013 | Total number of citations to all the publications attributed to the author (all types). |
|---|---|---|
| Self Citations | 730 | Citations where the author references their own previous work. |
| Self Citation Rate | 1.92 | Percentage of self-citations in the author's total citation count. |
| Non Self Citation Rate | 98.08 | Percentage of citations received from sources that are not self-citations. |
| Hot Citations | 1147 | Total number of citations recieved in the last 6 months. |
| Citations/Document | 50.96 | Average of citations recieved per document. |
| % Not Cited | 0.0 | Percentage of documents with no citations recieved. |
| Relative Citation Index | 3.541 | Item oriented indicator consisting of the quotient between the number of citations to a given work and the average number of citations to works of the same type, year and discipline. An author's RCI corresponds to the average of the values of his/her publications. |
| Journal Relative Citation Index | 2.137 | Item oriented indicator consisting of the quotient between the number of citations to a given work and the average number of citations to works of the same type, year and journal. An author's RCI corresponds to the average of the values of his/her publications. |
| H Index | 86 | Maximum value of h such that the given author has published at least h papers that have each been cited at least h times. |
| G Index | 181 | Maximum value of g such that the given author has published at least g papers that have each been cited at least g^2 times. |
| i10 Index | 345 | Number of documents with at least 10 citations recieved. |
Excellence
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
| Citation Score | 0.587 | Ratio between 0 and 1 being 0 corresponding to the citation percentile being 0 the 0th and 1 the 100th. |
|---|---|---|
| Citation Normalized Percentile | 0.586 | Citation percentile normalized to 1 (0 worst, 1 best) of the position in citations rankin within the field. Provided by OpenAlex. |
| Higly Cited Papers (top 10%) | 142 | Count of publications falling on or above the 90th citation percentile in the cohort of publications of the same type, year and discipline. |
| Relative Higly Cited Papers | 1.903 | Quotient between the real number of Highly Cited Papers (HCP) and expected number of HCP's that is the 10% of total documents. |
| Outstanding Papers (top 1%) | 31 | Count of publications falling on or above the 99th citation percentile in the cohort of publications of the same type, year and discipline. |
| Relative Outstanding Papers | 4.155 | Quotient between the real number of Outstanding Papers (OP) and expected number of OP's that is the 1% of total documents. |
| Outstanding Papers (top 0.1%) | 6 | Count of publications falling on or above the 99.9th citation percentile in the cohort of publications of the same type, year and discipline. |
| Hot Papers | 29 | Using only the citations recieved in the last 6 months: documents falling on or above the 99th citation percentile in the cohort of publications of the same type, year and discipline. |
Interaction within community
Leadership
Reflects an author's efforts and commitment in leading research initiatives.
| Docs Leadership | 258 | Number of documents lead by the author. |
|---|---|---|
| % Leadership | 34.58 | Percentage of documents lead by the author. |
| Docs International Leadership | 60 | Number of documents in international collaboration lead by the author. |
| % International Leadership | 8.04 | Percentage of documents in international collaboration lead by the author. |
| Principal Investigator | 0 | Number of times where the author served as the lead researcher in a project. |
| Associations Founded | 0 | Number of associations founded by the author. |
| Societies Founded | 0 | Number of scientific or professional societies established by the author. |
| Foundations Founded | 0 | Number of research-related foundations established by the author. |
| Councils | 0 | Number of councils founded by author. |
Cooperation
Reflects a researcher's ability to navigate and thrive in varied academic and research environments, highlighting adaptability, resourcefulness, and the capacity to build and maintain collaborative relationships across the spectrum of their career.
| Authors/Paper | 13.23 | Average number of authors per document. |
|---|---|---|
| % Highly Authored Papers | 4.02 | Percentage of documents with 25 or more authors. |
| Countries/Paper | 1.79 | Average number of different countries in the author's affiliation line per document. |
| Docs International Collaboration | 206 | Number of documents reporting two or more different countries in the author's affiliation line. |
| % International Collaboration | 27.61 | Percentage of documents reporting two or more diffetent countries in the author's affiliation line. |
Community Support
Reflects an author's contributions to the academic community beyond their own research.
| Peer Review Counts | 0 | Number of times the author peer-reviewed publications. |
|---|---|---|
| Society Membership | 4 | Number of societies of wich the author is a member. |
| Society Memberships | 0 | Memberships held by the author in scientific or professional societies. |
| Editorial Board Memberships | 0 | Number of journals where the author has been member of editorial board. |
| Panelists | 0 | Number of times the author have been a panelist in the European Research Council (ERC) calls. |
Community Recognition
Reflects the academic community's acknowledgment and appreciation of an author's contributions.
| Distinctions | 0 | Number of times the author have recieved a distinction for its career. |
|---|---|---|
| Invitations | 0 | Number of times the author has been invited to talks, professorships, expositions or demonstrations. |
| Talks | 0 | Number of times the author has been invited to talks. |
| Professorships | 0 | Number of times the author has been invited to professorhips. |
| Commissioned Reports | 0 | Commissioned reports done by the author. |
Interaction with society
Openness
Reflects an author's commitment to making their research freely accessible and open to the public.
| Open Access Documents | 312 | Number of documents in Open Access mode. |
|---|---|---|
| % Open Access Documents | 41.82 | Percentage of documents in Open Access mode. |
| Open Access Gold | 40 | Number of documents published in an OA journal that is indexed by the DOAJ. |
| Open Access Green | 19 | Toll-access on the publisher landing page, but there is a free copy in an OA repository. |
| Open Access Hybrid | 70 | Free under an open license in a toll-access journal. |
| Open Access Bronze | 183 | Free to read on the publisher landing page, but without any identifiable license. |
| Open Access Closed | 434 | Non Open Access documents. |
Transference
Reflects an author's commitment to making their research a practical application and real-world impact of an author's research.
| Patents | 0 | Intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an enabling disclosure of the invention. |
|---|---|---|
| Advisory Boards | 0 | Number of advisory boards of which the author is member. |
| Companies | 0 | Number of companies created or founded by the author. |
Fundraising
Reflects an author's ability in securing project funding from major global entities, showcasing your ability to drive research initiatives forward.
| Funding Counts | 1 | Number of activities reported as funding recieved. |
|---|---|---|
| ERC Grantees | 0 | Researchers awarded grants from the European Research Council. |